Alfuzosin for Treating Acute Urinary Retention

Inclusion Criteria: * First episode of painful AUR related to BPH requiring catheterization * Residual volume between 500ml and 1500ml obtained at the time of catheterization and during the first one hour after catheterization Exclusion Criteria: * Participated in another investigational study within 3 months before recruitment * Suspect bladder neuro-dysfunction unrelated to etiology; * Single Bladder neck disease; * Acute/chronic prostatitis; * Diagnosed prostate carcinoma; * Suspected prostate carcinoma diagnosed by ultrasound wave; * Surgical history of prostate and urethra; * Diagnosed/suspected abnormality in urethra structure; * Bladder stone; * Blood urine retention caused by any reason; * Residual volume less than 500 ml * Residual volume more than 1500 ml * AUR not due to BPH * Parkinson's disease * Insulin dependent diabetes * Known/suspected multiple sclerosis; * Stroke/MI within 6 months prior to enrolment; * AST, ALT and Creatinine \> 1.5x upper limit; neutrophil \< 3,000/mm³; platelet \< 100,000/mm³; * Unstable/severe heart failure; * History of postural hypertension/hypotension; * Known hypersensitivity to α-receptor blocker; * Suspected/diagnosed expansible nerval disease; * Treatment with sympathomimetic agent within 1 week prior to enrolment, except OTC drug for cold intermittently; * Treatment with α1-receptor blocker within 1 month prior to enrolment; * Treatment with tricyclic antidepressants, anticholinergic agents, sympathomimetic agent (other than the above reason), first generation antihistaminic, except the treatment with stable β sympathomimetic agent/ anticholinergic agents lasting more than 1 week for Asthma and COPD (Chronic Obstructive Pulmonary Disease); * Treatment with Disopyramide The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.